Art. 25 Regulation (EU) 2016/161

Obligations of persons authorised or entitled to supply medicinal products to the public

In forcesince 2 Oct 2015cited 10×
1.

Persons authorised or entitled to supply medicinal products to the public shall verify the safety features and decommission the unique identifier of any medicinal product bearing the safety features they supply to the public at the time of supplying it to the public.

2.

Notwithstanding paragraph 1, persons authorised or entitled to supply medicinal products to the public operating within a healthcare institution may carry out that verification and decommissioning at any time the medicinal product is in the physical possession of the healthcare institution, provided that no sale of the medicinal product takes place between the delivery of the product to the healthcare institution and the supplying of it to the public.

3.

In order to verify the authenticity of the unique identifier of a medicinal product and decommission that unique identifier, persons authorised or entitled to supply medicinal products to the public shall connect to the repositories system referred to in Article 31 through the national or supranational repository serving the territory of the Member State in which they are authorised or entitled.

4.

They shall also verify the safety features and decommission the unique identifier of the following medicinal products bearing the safety features:

(a)

medicinal products in their physical possession that cannot be returned to wholesalers or manufacturers;

(b)

medicinal products that, while in their physical possession, are requested as samples by competent authorities, in accordance with national legislation;

(c)

medicinal products which they supply for subsequent use as authorised investigational medicinal products or authorised auxiliary medicinal products as defined in Articles 2(2)(9) and (10) of Regulation (EU) No 536/2014.

  • Code de la sécurité socialel162-16-3-2Law

    … une pénalité financière en cas de manquement à l'obligation de désactivation de l'identifiant unique prévue à l'article 25 du règlement délégué (UE) 2016/161 de la Commission du 2 octobre 2015 complétant la directive 2001/83/ …

  • Règlement grand-ducal du 15 décembre 1992 relatif à la mise sur le marché des médicaments.10quinquiesLaw

    Nonobstant l’article 25 du règlement délégué (UE) 2016/161 de la Commission du 2 octobre 2015 complétant la directive 2001/83/CE du Parlement européen et du Conseil en fixant les modalités des dispositifs de sécurité figurant …

  • Opinion of Advocate General Szpunar delivered on 13 January 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    Last, having regard to all of the foregoing considerations, I propose that the Court answer the questions for a preliminary ruling referred by the Sø – og Handelsretten (Maritime and Commercial Court, Denmark) in Case C‑224/20 as …

    13 Jan 2022 · 62020CC0147

  • Décret n° 2023-1127 du 30 novembre 2023 relatif à la pénalité financière applicable aux…Law

    … les modalités des dispositifs de sécurité figurant sur l'emballage des médicaments à usage humain, notamment son article 25 ; Vu le code de la santé publique ; Vu le code de la sécurité sociale, notamment son article L. 162-16-3-2 …

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others.Decision

    Article 25 of Delegated Regulation 2016/161, entitled ‘Obligations of persons authorised or entitled to supply medicinal products to the public’, provides, in paragraphs 1 and 3: ‘1. Persons authorised or entitled to supply medicinal …

    17 Nov 2022 · 62020CJ0224

  • Judgment of the Court (Seventh Chamber) of 26 January 2023. Consejo General de Colegios Oficiales de Farmacéuticos de España (CGCOF) v AdminDecisioninterprets

    … detailed rules for the safety features appearing on the packaging of medicinal products for human use, in particular Articles 25, 31, 32, 35, 36 and 44 thereof, must be interpreted as not precluding national legislation providing for the …

    26 Jan 2023 · 62021CJ0469

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Bayer Intellectual Property GmbH v kohlpharma GmbH.Decision

    Article 25 of Delegated Regulation 2016/161, entitled ‘Obligations of persons authorised or entitled to supply medicinal products to the public’, provides, in paragraphs 1 and 3: ‘1. Persons authorised or entitled to supply medicinal …

    17 Nov 2022 · 62020CJ0204

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    Article 25 of Delegated Regulation 2016/161, entitled ‘Obligations of persons authorised or entitled to supply medicinal products to the public’, provides, in paragraphs 1 and 3: ‘1. Persons authorised or entitled to supply medicinal …

    17 Nov 2022 · 62020CJ0147

  • Arrêté du 26 février 2021 modifiant l'arrêté du 28 novembre 2016 relatif aux bonnes prat…Law

    … les modalités des dispositifs de sécurité figurant sur l'emballage des médicaments à usage humain, notamment ses articles 25, 26, 27, 28, 29 et 30 ; Vu le code de la santé publique, notamment son article L. 5121-5 ; Vu l'ordonnance …

  • Règlement grand-ducal du 13 janvier 2019 modifiant : 1° le règlement grand-ducal modifié…iLaw

    … 10quinquies. Nonobstant l’article 25 du règlement délégué (UE) 2016/161 de la Commission du 2 octobre 2015 complétant la directive 2001/83/CE du Parlement européen et du Conseil en fixant les modalités des dispositifs de …